Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
- 1 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Diabetologica
- Vol. 57 (7), 779-783
- https://doi.org/10.1007/s00592-020-01539-z
Abstract
Aims SARS-CoV-2 causes severe respiratory syndrome (COVID-19) with high mortality due to a direct cytotoxic viral effect and a severe systemic inflammation. We are herein discussing a possible novel therapeutic tool for COVID-19. Methods Virus binds to the cell surface receptor ACE2; indeed, recent evidences suggested that SARS-CoV-2 may be using as co-receptor, when entering the cells, the same one used by MERS-Co-V, namely the DPP4/CD26 receptor. The aforementioned observation underlined that mechanism of cell entry is supposedly similar among different coronavirus, that the co-expression of ACE2 and DPP4/CD26 could identify those cells targeted by different human coronaviruses and that clinical complications may be similar. Results The DPP4 family/system was implicated in various physiological processes and diseases of the immune system, and DPP4/CD26 is variously expressed on epithelia and endothelia of the systemic vasculature, lung, kidney, small intestine and heart. In particular, DPP4 distribution in the human respiratory tract may facilitate the entrance of the virus into the airway tract itself and could contribute to the development of cytokine storm and immunopathology in causing fatal COVID-19 pneumonia. Conclusions The use of DPP4 inhibitors, such as gliptins, in patients with COVID-19 with, or even without, type 2 diabetes, may offer a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.This publication has 50 references indexed in Scilit:
- Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-α in THP-1 Cells and MonocytesPLOS ONE, 2013
- Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responsesBMC Immunology, 2009
- Regulation of Expression and Function of Dipeptidyl Peptidase 4 (DP4), DP8/9, and DP10 in Allergic Responses of the Lung in RatsJournal of Histochemistry & Cytochemistry, 2007
- Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory SyndromeThe New England Journal of Medicine, 2003
- Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IVCritical Reviews in Clinical Laboratory Sciences, 2003
- Molecular characterization of dipeptidyl peptidase activity in serumJBIC Journal of Biological Inorganic Chemistry, 2000
- Apical Secretion and Sialylation of Soluble Dipeptidyl Peptidase IV Are Two Related EventsExperimental Cell Research, 2000
- Isolated and preclinical impairment of left ventricular filling in insulin-dependent and non-insulin-dependent diabetic patientsClinical Cardiology, 1997
- Radiation-induced chromosome non-disjunction in oocytes stimulated by different doses of superovulating hormonesMutation Research Letters, 1982
- A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-?-naphthylamideHistochemistry and Cell Biology, 1966